Statistical Analysis Plan for the Helmet Non-Invasive Ventilation for COVID-19 Patients (Helmet-COVID) Randomized Controlled Trial

Yaseen Arabi; Haytham Tlayjeh; Sara Aldekhyl; Hasan Al-Dorzi; Sheryl Ann Abdukahil; Jesna Jose; Mohammad Khulaif Al Harbi; Husain Al Haji; Mohammed Al Mutairi; Omar Al Zumai; Eman Al Qasim; Wedyan Al Wehaibi; Saad Al Qahtani; Mohammed Alshahrani; Talal Albrahim; Ahmed Mady; Ali Al Bshabshe; Zohair Al Aseri; Zainab Al Duhailib; Ayman Kharaba; Rakan Alqahtani; Haifa Algethamy; Omar Alfaris; Omar Alnafel; Abdulrahman A Al-Fares

doi:10.1101/2021.07.26.21260421

Abstract

Background and objective Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation having multiple advantages over other support modalities but data about effectiveness are limited.

Methods In this multicenter randomized trial of helmet non-invasive ventilation for COVID-19 patients (Helmet-COVID), 320 adult ICU patients with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (with a ratio of arterial oxygen partial pressure to fraction (percent) of inspired oxygen (PaO₂/FiO₂) <200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate >10 L/min or above) will be randomized to helmet-noninvasive ventilation with usual care or usual care alone. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction from 40% to 25%.

Conclusion Consistent with international guidelines, we developed a detailed plan to guide the analysis of the Helmet-COVID trial. This plan specifies the statistical methods for the evaluation of primary and secondary outcomes to facilitate unbiased analyses of clinical data.

Trial registration Clinicaltrials.gov: NCT04477668 (registered on July 20, 2020)

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Clinicaltrials.gov: NCT04477668

Funding Statement

The study is funded by King Abdullah International Medical Research Center (RC 20/306/R). The study sponsor does not have any role in the study design, collection, management, analysis, and interpretation of data as well as the writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study has been approved by the Institutional Review Boards of King Abdulaziz Medical City- Riyadh; Aseer Central Hospital-Abha; King Fahad Hospital-Madinah; King Abdulaziz University Hospital-Jeddah; King Faisal Specialist Hospital and Research Center- Riyadh; King Fahad Hospital of the University- Dammam; King Khalid University Hospital-Riyadh; King Salman Specialist Hospital-Hail; King Saud Medical City-Riyadh

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes